Ieq Capital LLC Acquires New Position in DexCom, Inc. $DXCM

Ieq Capital LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 92,014 shares of the medical device company’s stock, valued at approximately $6,197,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Callan Family Office LLC purchased a new stake in shares of DexCom during the 2nd quarter worth approximately $435,000. Allworth Financial LP purchased a new position in DexCom in the 2nd quarter valued at approximately $516,000. B. Metzler seel. Sohn & Co. AG purchased a new position in DexCom in the 2nd quarter valued at approximately $3,193,000. Silvant Capital Management LLC acquired a new position in DexCom during the second quarter worth $5,359,000. Finally, Trillium Asset Management LLC acquired a new position in DexCom during the second quarter worth $3,225,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Barclays restated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Royal Bank Of Canada increased their price target on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Stock Performance

NASDAQ DXCM opened at $92.34 on Monday. The business’s 50-day moving average price is $77.49 and its 200 day moving average price is $70.93. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.56. The company has a market capitalization of $34.85 billion, a PE ratio of 36.50, a price-to-earnings-growth ratio of 1.56 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.48 earnings per share. On average, research analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Transactions at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.